Advenchen 
Welcome,         Profile    Billing    Logout  
 4 Products   1 Disease   4 Products   526 Trials   2098 News 


«12345678910111213...3738»
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Journal:  Anlotinib Attenuates Liver Fibrosis by Regulating the Transforming Growth Factor ?1/Smad3 Signaling Pathway. (Pubmed Central) -  Sep 8, 2023   
    In animal experiments, anlotinib showed protective effects on the CCl4-induced liver damage, including ameliorating liver inflammation, reversing liver fibrosis and reducing liver enzymes. This is a very good signal, anlotinib may be useful for halting or reversing the progression of liver fibrosis and could be employed in the development of novel therapeutic drugs for the management of chronic liver diseases.
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Journal, Real-world evidence, Real-world, Metastases:  Safety and efficacy of anlotinib hydrochloride capsules in advanced non-small-cell lung cancer: a multicenter, real-world study. (Pubmed Central) -  Sep 7, 2023   
    This is a very good signal, anlotinib may be useful for halting or reversing the progression of liver fibrosis and could be employed in the development of novel therapeutic drugs for the management of chronic liver diseases. The median progression-free survival of patients in the monotherapy group was significantly lower than that in the combination group (5 vs 6
  • ||||||||||  Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
    Trial completion date, Trial initiation date, Trial primary completion date, Metastases:  ALTER-HN005: Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma (clinicaltrials.gov) -  Sep 6, 2023   
    P2,  N=110, Not yet recruiting, 
    These cases suggest that osimertinib is a promising treatment option for patients with EGFR 19 deletion-mutated lung adenocarcinoma and bone metastases, although further clinical studies are needed to confirm its efficacy. Trial completion date: Jun 2025 --> Oct 2025 | Initiation date: Jun 2023 --> Oct 2023 | Trial primary completion date: Jun 2024 --> Oct 2024
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Is Neoadjuvant Chemotherapy Useful in Primary Pulmonary Artery Synovial Sarcoma? (In-Person) -  Sep 4, 2023 - Abstract #CAP2023CAP_523;    
    Anlotinib was administered orally during the period of chemotherapy...Histopathologic features of viable tumor were similar to the previous biopsy. Our experience suggests that neoadjuvant chemotherapy should be considered to improve resectability in cases of borderline resectable pulmonary artery sarcoma.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Hand-foot syndrome induced by Pembrolizumab for non-small cell lung cancer (e-Poster Hall) -  Aug 30, 2023 - Abstract #EADV2023EADV_2365;    
    HFS has been described in the literature as an uncommon side effect of many anti-tumor drugs including pembrolizumab but always in combination with other drugs such as capecitabine, lenvatinib and anlotinib. There are no reports in literature concerning the development of HFS as side effect of pembrolizumab in monotherapy, thus our report may help researcher to improve the side effect profile of the immunotherapeutic agent that is nowadays considered a novel and encouraging tool against cancer.
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Preclinical, Journal:  Anlotinib exerts an anti-T-cell acute lymphoblastic leukemia effect in vitro and in vivo. (Pubmed Central) -  Aug 28, 2023   
    There are no reports in literature concerning the development of HFS as side effect of pembrolizumab in monotherapy, thus our report may help researcher to improve the side effect profile of the immunotherapeutic agent that is nowadays considered a novel and encouraging tool against cancer. The present study showed that anlotinib may be a promising anti-T-ALL candidate drug, and simultaneous reduction of the protein levels of both ICN1 and c-Myc may contribute to the anti-T-ALL efficacy of anlotinib.
  • ||||||||||  Review, Journal:  Small molecule protein kinase inhibitors approved by regulatory agencies outside of the United States. (Pubmed Central) -  Aug 21, 2023   
    Although the efficacy of imatinib in the treatment of chronic myelogenous leukemia in the United States in 2001 was the main driver of protein kinase inhibitor drug discovery, this was preceded by the approval of fasudil (a ROCK antagonist) in Japan in 1995 for the treatment of cerebral vasospasm...One-third of the 21 internationally approved drugs are not compliant with Lipinski's rule of five for orally bioavailable drugs. The rule of five relies on four parameters including molecular weight, number of hydrogen bond donors and acceptors, and the Log of the partition coefficient.
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Journal:  "One-stop" synergistic strategy for hepatocellular carcinoma postoperative recurrence. (Pubmed Central) -  Aug 11, 2023   
    Subsequently, SQAP was constructed by loading black phosphorus nanosheets (BPNSs) and anlotinib hydrochloride (AL3818) based on SQ-50...Furthermore, in vivo studies indicated that the NIR-assisted SQAP prevented local recurrence of ectopic HCC after surgical resection, achieved through the synergistic effect of mPTT and molecular targeted therapy. Thus, the multifunctional SQAP provides a "one-stop" synergistic strategy for HCC postoperative recurrence, showing great potential for clinical application.
  • ||||||||||  Tevimbra (tislelizumab) / BeiGene, Focus V (anlotinib) / Advenchen, Sino Biopharm
    New P2 trial, Metastases:  Anrotinib and Tirelizumab in First-line Treatment of RM-NPC (clinicaltrials.gov) -  Aug 8, 2023   
    P2,  N=27, Recruiting, 
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Trial completion date, Trial primary completion date, Monotherapy, Metastases:  Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) (clinicaltrials.gov) -  Aug 1, 2023   
    P3,  N=325, Active, not recruiting, 
    This indicate that comprehensive treatment including immunotherapy may be helpful for inoperable DMPM patients with nasopharyngeal carcinoma accompanied with paraneoplastic syndromes. Trial completion date: Apr 2023 --> Apr 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Enrollment open, Metastases:  Anlotinib Maintenance Treatment for Advanced Soft Tissue Sarcoma (clinicaltrials.gov) -  Aug 1, 2023   
    P2,  N=48, Recruiting, 
    Trial completion date: Apr 2023 --> Apr 2024 | Trial primary completion date: Dec 2022 --> Dec 2023 Active, not recruiting --> Recruiting
  • ||||||||||  Review, Journal:  Indole Antitumor Agents in Nanotechnology Formulations: An Overview. (Pubmed Central) -  Jul 29, 2023   
    Additionally, new drug delivery systems have been developed to protect the active principle from degradation and to direct the drug to the specific site for clinical use, thus reducing its toxicity. In the present work is an updated review of the recently approved indole-based anti-cancer agents and the nanotechnology systems developed for their delivery.
  • ||||||||||  Tevimbra (tislelizumab) / BeiGene, Novartis, Focus V (anlotinib) / Advenchen, Sino Biopharm
    Combinationof Anlotinib and Tislelizumab for Lung Adenocarcinoma: Effects on Metabolic and Flora Microenvironment (Exhibit Hall) -  Jul 29, 2023 - Abstract #IASLCWCLC2023IASLC_WCLC_2468;    
    The results of this study show that combination therapy can effectively activate immune cells, inhibit neovascularization, and cause changes in intestinal flora and metabolites in vivo. In addition, we identified combination therapy-related genes and signaling pathways, which provide a basis for clinical individualization and comprehensive treatment.